Literature DB >> 23099354

A mouse model reveals an important role for catecholamine-induced lipotoxicity in the pathogenesis of stress-induced cardiomyopathy.

Yangzhen Shao1, Björn Redfors, Marcus Ståhlman, Margareta Scharin Täng, Azra Miljanovic, Helge Möllmann, Christian Troidl, Sebastian Szardien, Christian Hamm, Holger Nef, Jan Borén, Elmir Omerovic.   

Abstract

AIM: Stress-induced cardiomyopathy (SIC), also known as takotsubo cardiomyopathy, is an acute cardiac syndrome with substantial morbidity and mortality. The unique hallmark of SIC is extensive ventricular dysfunction (akinesia) involving apical segments with preserved function in basal segments. Adrenergic overstimulation plays an important role in initiating SIC, but the pathomechanisms involved are unknown. We tested the hypothesis that excessive catecholamines cause perturbation of myocardial lipid metabolism and that cardiac lipotoxicity is responsible for the pathogenesis of SIC. METHODS AND
RESULTS: A single dose injection of isoprenaline (ISO; 400 mg/kg) induced SIC-like regional akinesia in mice. Oil red O staining revealed severe lipid accumulation in the heart 2 h post-ISO. Both intramyocardial lipid accumulation and cardiac function were normalized within 1 week post-ISO and no significant amount of fibrosis was detected. We found that gene expression of lipid importers and exporters (ApoB lipoprotein) was depressed 2 h post-ISO. These results were confirmed by similar findings in SIC patients and in ISO/patient serum-stressed HL-1 cardiomyocytes. Moreover, overexpression of ApoB in the heart was found to protect against the development of ISO-induced cardiac toxicity and cardiac dysfunction. We also found that ISO-induced intramyocardial lipid accumulation caused electrophysiological disturbance and stunning in ISO/patient serum-stressed HL-1 cardiomyocytes.
CONCLUSIONS: The present study demonstrates that lipotoxicity is closely associated with catecholamine-induced myocardial dysfunction, including neurogenic stunning, metabolic stunning, and electrophysiological stunning. Cardiac lipotoxicity may originate from direct inhibition of myocardial ApoB lipoprotein and subsequent decreased lipid export, caused by supraphysiological levels of catecholamines.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23099354     DOI: 10.1093/eurjhf/hfs161

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  23 in total

Review 1.  Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection.

Authors:  Hans Erik Bøtker; Derek Hausenloy; Ioanna Andreadou; Salvatore Antonucci; Kerstin Boengler; Sean M Davidson; Soni Deshwal; Yvan Devaux; Fabio Di Lisa; Moises Di Sante; Panagiotis Efentakis; Saveria Femminò; David García-Dorado; Zoltán Giricz; Borja Ibanez; Efstathios Iliodromitis; Nina Kaludercic; Petra Kleinbongard; Markus Neuhäuser; Michel Ovize; Pasquale Pagliaro; Michael Rahbek-Schmidt; Marisol Ruiz-Meana; Klaus-Dieter Schlüter; Rainer Schulz; Andreas Skyschally; Catherine Wilder; Derek M Yellon; Peter Ferdinandy; Gerd Heusch
Journal:  Basic Res Cardiol       Date:  2018-08-17       Impact factor: 17.165

2.  The stress-related hormone norepinephrine induced upregulation of Nix, contributing to ECM protein expression.

Authors:  Weili Liu; Xinxing Wang; Jingbo Gong; Zhusong Mei; Xiujie Gao; Yun Zhao; Jing Ma; Lingjia Qian
Journal:  Cell Stress Chaperones       Date:  2014-05-07       Impact factor: 3.667

Review 3.  Neurogenic Stunned Myocardium in Severe Neurological Injury.

Authors:  Benjamin B Kenigsberg; Christopher F Barnett; Jeffrey C Mai; Jason J Chang
Journal:  Curr Neurol Neurosci Rep       Date:  2019-11-13       Impact factor: 5.081

4.  Exploring the Pattern of Metabolic Alterations Causing Energy Imbalance via PPARα Dysregulation in Cardiac Muscle During Doxorubicin Treatment.

Authors:  Kaviyarasi Renu; Sathishkumar Vinayagam; Harishkumar Madhyastha; Radha Madhyastha; Masugi Maruyama; Shubhankar Suman; Sankarganesh Arunachalam; Balachandar Vellingiri; Abilash Valsala Gopalakrishnan
Journal:  Cardiovasc Toxicol       Date:  2022-02-14       Impact factor: 3.231

5.  Broken heart syndrome, neurogenic stunned myocardium and stroke.

Authors:  Amit S Dande; Amrita S Pandit
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-06

6.  Acute Catecholamine Exposure Causes Reversible Myocyte Injury Without Cardiac Regeneration.

Authors:  Markus Wallner; Jason M Duran; Sadia Mohsin; Constantine D Troupes; Davy Vanhoutte; Giulia Borghetti; Ronald J Vagnozzi; Polina Gross; Daohai Yu; Danielle M Trappanese; Hajime Kubo; Amir Toib; Thomas E Sharp; Shavonn C Harper; Michael A Volkert; Timothy Starosta; Eric A Feldsott; Remus M Berretta; Tao Wang; Mary F Barbe; Jeffrey D Molkentin; Steven R Houser
Journal:  Circ Res       Date:  2016-07-26       Impact factor: 17.367

Review 7.  Physiological and pathological roles of protein kinase A in the heart.

Authors:  Yuening Liu; Jingrui Chen; Shayne K Fontes; Erika N Bautista; Zhaokang Cheng
Journal:  Cardiovasc Res       Date:  2022-01-29       Impact factor: 10.787

8.  Metabolic alterations in a rat model of takotsubo syndrome.

Authors:  Nadine Godsman; Michael Kohlhaas; Alexander Nickel; Lesley Cheyne; Marco Mingarelli; Lutz Schweiger; Claire Hepburn; Chantal Munts; Andy Welch; Mirela Delibegovic; Marc Van Bilsen; Christoph Maack; Dana K Dawson
Journal:  Cardiovasc Res       Date:  2022-06-29       Impact factor: 13.081

9.  Efficacy and safety of levosimendan in Chinese elderly patients with Takotsubo syndrome.

Authors:  Yi Guo; Chaofei Zhou; Xia Yang
Journal:  Ann Transl Med       Date:  2018-11

10.  Trigger-Specific Remodeling of KCa2 Potassium Channels in Models of Atrial Fibrillation.

Authors:  Ann-Kathrin Rahm; Dominik Gramlich; Teresa Wieder; Mara Elena Müller; Axel Schoeffel; Fadwa A El Tahry; Patrick Most; Tanja Heimberger; Steffi Sandke; Tanja Weis; Nina D Ullrich; Thomas Korff; Patrick Lugenbiel; Hugo A Katus; Dierk Thomas
Journal:  Pharmgenomics Pers Med       Date:  2021-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.